TY - JOUR T1 - Therapeutic options for operated adenocarcinoma patients in stages I or II JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - P4199 AU - Anastasios Palamidas AU - Sophia - Antiopi Gennimata AU - Fotis Vlastos AU - Nikolaos Koulouris AU - Jean-Michel Vigneaud AU - Nadine Martinet Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/P4199.abstract N2 - Surgery is the only radical option for NSCLC therapeutic management. We studied the survival rates of operated NSCLC patients followed in the context of the ISO certified Nancy lung cancer biobank. During a period of 20 years, 26 patients (age = 59 ± 9 years, p.yrs = 38 ± 25, survival months = 30 ± 15) were reoperated upon for curative purposes. The survival rates of these patients were compared to those of a matched control group of 26 NSCLC patients (age = 61 ± 7 years, p.yrs = 45 ± 26, survival months = 31 ± 16) operated upon only once and no statistical significant difference was detected. Both groups received post-operation chemo-radiotherapy during the course of their disease. We also studied the survival rates of the most prevalent histotypes of these groups of NSCLC patients such as adenocarcinoma and squamous cell carcinoma. For patients with squamous cell carcinoma group, there was no statistical difference in survival between reoperated and once-operated patients in all stages. Nevertheless, for adenocarcinoma patients there was statistical significant difference in survival rates of 12 months favoring the reoperated patients in stages I – II (p = 0.0048). No statistical difference was presented between the lung adenocarcinoma groups in stages III – IV. We concluded that reoperation should remain an option for previously operated adenocarcinoma patients who are presented in stages I or II as their survival is expected to be longer in comparison to those who receive only post-operation chemo-radiotherapy. ER -